migraine headache

Sumatriptan succinate (GR 43175), a serotonin1 (5-HT1) receptor agonist, is used in the acute treatment of a migraine headache.

Frovatriptan is a highly potent and cerebroselective agonist of the 5-HT1B/1D receptors, demonstrating the greatest receptor potency among clinically used triptan compounds, and it robustly activates serotonergic signaling pathways to modulate cranial vasoconstriction and trigeminal neurotransmission relevant to migraine pathophysiology, while showing demonstrated clinical efficacy and, in certain predefined endpoints, superiority when administered during the headache phase of migraine attacks accompanied by aura, supporting the optimized pharmacodynamic profile for targeted antimigraine therapy and translational neuropharmacology research.

RI 61 (sumatriptan succinate) is utilized in the therapy of migraine, cluster headaches, new daily persistent headache, and cyclic vomiting syndrome.

Sumatriptan (GR 43175) hydrochloride can be used in the research of migraine headache that is an orally active agonist of 5-HT1 receptor. The Ki values of Sumatriptan hydrochloride against 5-HT1D, 5-HT1B and 5-HT1A receptors are 17 nM, 27 nM and 100 nM, respectively. [1] [2].